Company Filing History:

8 out of 43

Vernalis Research Limited

patents

2 out of 4,948

Hoffmann-La Roche Inc.

patents

where one patent can have more than one assignee

Years Active: 2002-2009

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7504522 - Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders (2009-03-17),

2. 7452894 - Purine derivatives as purinergic receptor antagonists (2008-11-18),

3. 7384949 - Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists (2008-06-10),

4. 7323466 - Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity (2008-01-29),

5. 7022707 - Piperazine derivatives (2006-04-04),

6. 6828318 - 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission (2004-12-07),

7. 6787541 - Thieno-and furopyrimidine derivatives as A2A-receptor antagonists (2004-09-07),

8. 6380238 - Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands (2002-04-30),

Certainly! Here is the article about inventor Claire Elizabeth Dawson:

Title: Innovator Spotlight: Claire Elizabeth Dawson - Revolutionizing Treatment in CB1 Receptor Mediated Disorders

Introduction:

Claire Elizabeth Dawson, an esteemed inventor hailing from Wokingham, GB, is making waves in the pharmaceutical industry with her groundbreaking patents and innovative solutions. With a total of 8 patents under her belt, Claire's latest inventions in the field of Azetidinecarboxamide derivatives and Purine derivatives are set to revolutionize the treatment of CB1 receptor mediated disorders.

Latest Patents:

Claire's recent patents include the development of Azetidinecarboxamide derivatives for the treatment of disorders mediated by CB1 receptors such as obesity. The formula (I) compounds show promising results in therapy, providing hope for patients suffering from such conditions. Additionally, her Purine derivatives as purinergic receptor antagonists offer new possibilities in treating movement disorders like Parkinson's disease, depression, cognitive impairments, and more.

Career Highlights:

Throughout her career, Claire has made significant contributions to the field of pharmaceuticals. She has worked with reputable companies such as Vernalis Research Limited and Hoffmann-La Roche Inc., where her expertise and dedication have led to groundbreaking discoveries in drug development and treatment methodologies.

Collaborations:

In her journey towards innovation, Claire has collaborated with esteemed professionals like Robert Mark Pratt and Roger John Gillespie. Together, they have pooled their knowledge and skills to push the boundaries of pharmaceutical research and development, paving the way for novel solutions in healthcare.

Conclusion:

Claire Elizabeth Dawson's relentless pursuit of innovation and her remarkable contributions to the pharmaceutical industry highlight her as a trailblazer in the field of CB1 receptor mediated disorders. Her patents not only showcase her expertise but also signify a brighter future for those in need of advanced medical treatments. Claire's work serves as an inspiration for aspiring inventors and researchers, embodying the spirit of progress and ingenuity in the quest for better healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com